There are many well dressed men and beautiful ladies going in and out of Tyler Collison office.
It seems that there is a lot of work going on with Partnering. There are loads of black rollable suItcases to suIt the eyes of the faIthful shareholders.
The goal Is to secure a good amount of cash and dIrect company investment to fInance the:
VLU FDA Phase III TrIal
DFU Phase II TrIal
Ocular FDA Orphan status TrIal
and some other grave Illnesses curable wIth OUR very valuable VF000X bIologIcal proteIn.
Let's guess who of the elected could be:
From the USA Johnson & Johnson is a top line partner. The resonance of such big name would be by itself a huge catalyst in the USA market and a free marketing for our company.
Smith & Nephew is good, but being the USA the first world market, with an impressive amount of obese and diabetic people (almost 40% are obese with circulatory disorders and VLU or DFU potential complications in any time of their life), I personally would love to see a major USA company in FTT.
The participation of J&J in our projects would open the door to some big US funds.
There is even a possibility of a split arrangement with two players. I have seen this in past between J&J and Abbvie. One could concentrate on the US, the other to Europe, but the contract in this case would require substantial more work.
Tyler Collison is in the game.
FTT Price at posting:
7.3¢ Sentiment: Buy Disclosure: Held
